secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2026-07-21T21:24:31+00:00
Accession:  0001711279-26-000050
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech discloses single-patient data from discontinued KB801 study in patent response
--------------------------------------------------------------------------------

- Filed response to USPTO Office Action for KB801 patent application; included data from one patient in discontinued clinical study.
- Patient experienced complete closure of persistent corneal epithelial defect after KB801 treatment.
- Study discontinued to advance KB801 into pivotal trial; no safety concerns or serious adverse events observed.
- Company cautions that single-patient observation is not top-line results and no conclusions on safety/efficacy should be drawn.
- Pivotal trial results for KB801 expected to be reported in ordinary course.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127926000050/0001711279-26-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127926000050/krys-20260721.htm
  HTML page:      https://secwatch.observer/filing/0001711279-26-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer